SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.
Checked against the public recordLast updated Oct 5, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Stemcentrx
- Interventions being studied
- Drug: SC-002
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment * Evidence of progressive disease during or following no more than 2 prior chemotherapy regimens * Measurable disease as defined by RECIST * ECOG performance status of 0 or 1 * Adequate hematological and organ function as confirmed by laboratory values * Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of SC-002 Exclusion Criteria: * Active central nervous system metastases * Uncontrolled cardiac disease * Positive serology for hepatitis B or hepatitis C or known HIV infection * Presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Study locationAnn Arbor, Michigan
- Study locationSt Louis, Missouri
- Study locationNew York, New York
- Study locationNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 5, 2018. Always confirm current availability with the study team.